AMGEN´s DE Website recently relaunched
The healthcare industry is extremely complex
- regulatory issues
- direct-to-patient marketing and
- the powerful bond of privacy and trust between providers and patients.
You know – we know
AMG, AMNOG, ATC, Benefit Assessment of Pharmaceuticals, BfArM, Biologics, Biosimilars, BLA, BMG, Breakthrough Therapy Designation, CHMP, CME, Compassionate Use, Compliance, DocCheck, EC, EMA, EPAR, FDA, G-BA, Generic, HCP, HWG, ICD-10, INN, IQWiG, Labelling, Lay Audience, Leaflet, MAA, MHRA, NCI, NDA, NICE, NIH, NPP (§ 73,3 AMG), NUB, OD, Off-Label-Use, Orphan Drugs, OL, OTC, PBM, PDUFA, PEI, Pharmacovigilance, Positive Opinion, Priority Review Designation, RA, Recombinant, Reference Prices, SGB V, Small Molecule …